APOLLOHOSP.NS Stock Today: February 11 – Q3 Beat, Dividend Sparks 6% Rally

Apollo Hospitals share price spiked intraday after a strong Q3 FY26 beat and a fresh dividend. APOLLOHOSP.NS opened at ₹7,405, hit ₹7,640, and last traded near ₹7,507, up ₹296 or 4.10%. Net profit rose 35% year on year to ₹502 crore, revenue grew 17% to ₹6,477 crore, and an interim dividend of ₹10 per share was declared. The move puts Apollo above its 50 and 200-day averages, while traders eye the 52-week high of ₹8,099.50 for follow-through.

Q3 FY26 highlights and dividend

Net profit grew 35% YoY to ₹502 crore on 17% revenue growth to ₹6,477 crore, beating street expectations. Broker commentary flagged expanding margins and lower digital losses, which aided sentiment. The performance supports a stronger hospital mix and scale benefits. For headline numbers and market reaction, see this recap from Upstox.

Management announced an interim dividend of ₹10 per share. On today’s price of ₹7,507, that implies a 0.13% one-off yield. The trailing twelve-month dividend is ₹19, a 0.26% yield. While yield is modest, regular payouts signal confidence in cash flows. Investors should watch for the record date and any update on capital allocation between expansion, debt reduction, and shareholder returns.

Stock move and technical setup

Apollo Hospitals share price rallied up to 6% intraday, and is currently up 4.10% at ₹7,507. The stock printed a high of ₹7,640 and a low of ₹7,405. Volume surged to 14,96,488 shares versus a 3,67,193 average, indicating strong participation. Price is above the 50-DMA at ₹7,080 and the 200-DMA at ₹7,348, keeping the near-term bias positive.

RSI is 60.47, ADX is 30.21 indicating a strong trend, and the MACD histogram turned positive at 40.58. CCI is 175.65 and price sits above the Bollinger upper band at ₹7,254.21, both showing overbought conditions. ATR is ₹120, suggesting active intraday swings. Traders may trail stops near ₹7,350 and reassess on any close back inside the bands.

International expansion and outlook

Management is pursuing an asset-light international push in Iraq, Tanzania, and Indonesia, building partnerships to scale without heavy capex. This can widen referrals and brand reach while protecting returns. The plan adds visibility to medium-term growth, as reported by the Times of India.

Potential re-rating rests on sustained margin gains, reduced digital losses, and early wins from international tie-ups. Internal forecasts point to ₹8,582.87 over a year and ₹10,350.10 in three years, though these are projections, not guarantees. With a PE of 62.18 and PB of 11.41, execution must stay strong to justify premium valuations.

Fundamentals and valuation check

Return on equity is 19.74% with a net margin of 7.19%. Interest coverage stands at 12.60x and net debt to EBITDA is 2.12x, supported by a current ratio of 1.64. Market cap is about ₹1.04 lakh crore. Price to sales is 4.46 and EV/EBITDA is 34.89. The 52-week range is ₹6,001 to ₹8,099.50, framing risk and reward.

Meyka’s stock grade is B+ (Score 78.24) with a BUY suggestion, reflecting growth and sector standing. The company rating on 10 Feb 2026 is B with a Neutral stance, noting high PE and PB. The PEG of 9.92 implies rich pricing. Apollo Hospitals share price may need steady earnings upgrades to sustain multiples.

Final Thoughts

Apollo Hospitals share price reacted to a clean Q3 beat, stronger margins, and a ₹10 interim dividend. Price sits above key moving averages with strong breadth, yet several indicators flash overbought. For investors, a staggered approach can help manage volatility while tracking execution on hospital margins, digital loss reduction, and the asset-light international rollout. Traders can watch ₹7,640 and ₹8,099.50 as resistance, with supports near ₹7,350 and ₹7,080. Valuation is full at a 62.18 PE, so sustained upgrades matter. Align entries with your risk, time horizon, and asset mix.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.